Attracts Biotechnology Company From South Korea, Kalbe Farma Facilitates Immuncell-LC Entry In Indonesia

Cooperation between Kalbe Farma and South Korean company GC Cell (Photo: Kalbe Farma)

JAKARTA - PT Kalbe Farma Tbk (KLBF) through Regenic which is supported by Kalbe's subsidiary, PT Bifarma Adiluhung (Bifarma) inaugurated a strategic partnership with GC Cell. GC Cell is a global biotechnology company in South Korea with a focus on cell therapy business.

The agreement in this strategic partnership aims to facilitate the entry of Immuncell-LC in Indonesia. Immuncell-LC is a cell therapy innovation that uses autologous T cell therapy and has received approval for use for liver cancer surgery in Korea.

In addition, the agreement between Bifarma and GC Cell also includes technology transfer and cooperation in the development of the Natural Killer (NK) Cells therapy pipeline which has scientifically proven to be able to work effectively in killing cancer cells.

"We announce that Bifarma, through our cell therapy division, Regenic, has signed a partnership agreement with GC Cell, a pioneer biopharmaceutical company from Korea. This strategic collaboration is an important milestone for our company, as well as strengthening our mission to provide safe, high-quality, and leading cell therapy," said President Director of PT Bifarma Adiluhung dr. Sandy Qlintang, MBiomed in a written statement, Thursday, June 20.

Meanwhile, GC Cell CEO James Park added that this partnership is proof of global recognition of his party's expertise as a pioneer in cell therapy in Korea.

"We believe that by combining integrated cell and gene therapy in GC Cell and Bifarma's capabilities and advantages in Indonesia, we are ready to immediately reach the leading position in the field of anti-cancer cell therapy," said James.

The availability of Immuncell-LC therapy is expected to facilitate and expand access to treatment for patients in Indonesia. Moreover, in Indonesia, liver cancer is the fourth deadly disease.

Hatu erap cancer is known as the silent killer because the symptoms are not easily known and the worsening of the disease is relatively fast. The number of deaths due to liver cancer cases in Indonesia is also high, reaching 21,392 people (Globocan 2020 Data).

In the future, both Regenic and GC Cell hope that this strategic partnership can strengthen the mission to transform health services, especially so that liver cancer patients can get optimal treatment for the better quality of life.